A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

NCT07140744 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

7000

Enrollment

INDUSTRY

Sponsor class

Conditions

Subjective Cognitive Impairment

Interventions

DIAGNOSTIC_TEST: P-tau217
OTHER: Standard of Care

Sponsor

Eli Lilly and Company